Lori McNeill - Dec 11, 2023 Form 4 Insider Report for Sonnet BioTherapeutics Holdings, Inc. (SONN)

Role
Director
Signature
/s/ John Harry Cross III, power of attorney
Stock symbol
SONN
Transactions as of
Dec 11, 2023
Transactions value $
$0
Form type
4
Date filed
12/5/2024, 09:55 PM
Previous filing
Dec 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SONN Common Stock Award +373 +1776.19% 394 Dec 11, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 11, 2023, the Reporting Person was granted 373 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025.
F2 Includes unvested restricted stock units.
F3 All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.